This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Novel Cancer Immune Therapy Developer Oncos Therapeutics Appoints Experienced Industry Leader Frans Wuite As President And CEO

HELSINKI, Finland, November 9, 2012 /PRNewswire/ --

Oncos Therapeutics Ltd., a company developing novel cancer immune therapeutics, announced today that it has appointed Frans Wuite, M.D., M.B.A, as President and Chief Executive Officer and Pekka Simula, M.Sc. (Tech) as Chief Operating Officer.

Frans Wuite brings more than 25 years of leadership experience that spans from start-up to large international companies within the biopharmaceutical industry to Oncos Therapeutics. Prior to joining Oncos, Wuite served in key leadership roles at companies in rapid growth phases. These included Warren and Araim Pharmaceuticals Inc, which he co-founded; Amgen Europe, where he spearheaded the commercial development and launch of Aranesp that rapidly became Amgen's biggest product; and the leadership of Pharmacia-Leiras, a marketing and sales joint venture in 13 European countries.

Pekka Simula, the founding CEO of Oncos since 2008, has successfully built Oncos into a clinical stage company. In his new role as Chief Operating Officer, Simula will be responsible for the company's overall program management covering research, clinical development, process development, and manufacturing.

Prior to co-founding Oncos, Simula was Global Program Manager at Varian Medical Systems (NYSE: VAR) responsible for the development and market roll-out of the company's entire oncology product suite and also held a central role in development of RapidArc™, the latest revolution in radiation oncology. Before Varian, he worked as  Project Director for CRF Health, a leading electronic Patient Reported Outcomes technology and services provider for clinical trials, and as Project Manager for Accenture.

About Oncos Therapeutics

Oncos Therapeutics develops personalized cancer immunotherapeutics based on its proprietary oncolytic adenovirus technology. The Company has clinical experience on 10 purposefully engineered vaccines. These have a direct oncolytic effect due to selective virus replication in tumor cells as well as systemic effects through vascular dissemination to metastases and induction of a strong immune response against tumor cells mediated by exposure of tumor antigens by oncolysis.  In addition, most of Oncos product candidates have a transgene that result in cytokine production in only cancer cells, e.g. GM-CSF, further enhancing the immune response against tumor cells.  Oncos' oncolytic vaccine portfolio will be focused on carefully selected cancer types that respond poorly to conventional therapies.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,005.22 +92.93 0.55%
S&P 500 1,995.83 +15.91 0.80%
NASDAQ 4,785.7440 -5.4080 -0.11%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs